Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Reata Hopes To Beat Competition To Market With Abbott Deals

Related Content

Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs

Dec 12 2011

Reata Readies Bardoxolone For Phase III Looking At Kidney Function Outcomes

Jun 24 2011

Reata Presents Bardoxolone Study Data That Spurred Abbott Deal

Nov 20 2010

Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug

Sep 23 2010

Related Companies

Reata Pharmaceuticals, Inc.

Abbott

Biogen, Inc.

Additional Topics

Business Strategies Clinical Trials Deals BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window